The Experts below are selected from a list of 8949 Experts worldwide ranked by ideXlab platform

Seungjae Myung - One of the best experts on this subject based on the ideXlab platform.

  • change of fecal Flora and effectiveness of the short term vsl 3 probiotic treatment in patients with functional constipation
    Journal of Neurogastroenterology and Motility, 2015
    Co-Authors: Seong Eun Kim, Suck Chei Choi, Kyung Sik Park, Moo In Park, Jeong Eun Shin, Tae Hee Lee, Kee Wook Jung, Hoon Sup Koo, Seungjae Myung
    Abstract:

    Background/aims We investigated Gut Flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on Flora and symptom improvement. Methods Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and Flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. Results The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P Conclusions Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering Gut Flora to allevate constipation.

  • change of fecal Flora and effectiveness of the short term vsl 3 probiotic treatment in patients with functional constipation
    Journal of Neurogastroenterology and Motility, 2015
    Co-Authors: Suck Chei Choi, Kyung Sik Park, Moo In Park, Jeong Eun Shin, Kee Wook Jung, Seungjae Myung
    Abstract:

    Background/aims: We investigated Gut Flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on Flora and symptom improvement. Methods: Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and Flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. Results: The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P < 0.001). Relief of subjective CSBM frequency, stool consistency and abdominal bloating were reported in 70%, 60%, and 47% of patients. After VSL#3 cessation, 44.4% of patients with symptom improvement experienced constipation recurrence mostly within one month. Conclusions: Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering Gut Flora to allevate constipation.

Georges K Christophides - One of the best experts on this subject based on the ideXlab platform.

Suck Chei Choi - One of the best experts on this subject based on the ideXlab platform.

  • change of fecal Flora and effectiveness of the short term vsl 3 probiotic treatment in patients with functional constipation
    Journal of Neurogastroenterology and Motility, 2015
    Co-Authors: Seong Eun Kim, Suck Chei Choi, Kyung Sik Park, Moo In Park, Jeong Eun Shin, Tae Hee Lee, Kee Wook Jung, Hoon Sup Koo, Seungjae Myung
    Abstract:

    Background/aims We investigated Gut Flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on Flora and symptom improvement. Methods Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and Flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. Results The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P Conclusions Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering Gut Flora to allevate constipation.

  • change of fecal Flora and effectiveness of the short term vsl 3 probiotic treatment in patients with functional constipation
    Journal of Neurogastroenterology and Motility, 2015
    Co-Authors: Suck Chei Choi, Kyung Sik Park, Moo In Park, Jeong Eun Shin, Kee Wook Jung, Seungjae Myung
    Abstract:

    Background/aims: We investigated Gut Flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on Flora and symptom improvement. Methods: Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and Flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. Results: The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P < 0.001). Relief of subjective CSBM frequency, stool consistency and abdominal bloating were reported in 70%, 60%, and 47% of patients. After VSL#3 cessation, 44.4% of patients with symptom improvement experienced constipation recurrence mostly within one month. Conclusions: Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering Gut Flora to allevate constipation.

Kyung Sik Park - One of the best experts on this subject based on the ideXlab platform.

  • change of fecal Flora and effectiveness of the short term vsl 3 probiotic treatment in patients with functional constipation
    Journal of Neurogastroenterology and Motility, 2015
    Co-Authors: Seong Eun Kim, Suck Chei Choi, Kyung Sik Park, Moo In Park, Jeong Eun Shin, Tae Hee Lee, Kee Wook Jung, Hoon Sup Koo, Seungjae Myung
    Abstract:

    Background/aims We investigated Gut Flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on Flora and symptom improvement. Methods Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and Flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. Results The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P Conclusions Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering Gut Flora to allevate constipation.

  • change of fecal Flora and effectiveness of the short term vsl 3 probiotic treatment in patients with functional constipation
    Journal of Neurogastroenterology and Motility, 2015
    Co-Authors: Suck Chei Choi, Kyung Sik Park, Moo In Park, Jeong Eun Shin, Kee Wook Jung, Seungjae Myung
    Abstract:

    Background/aims: We investigated Gut Flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on Flora and symptom improvement. Methods: Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and Flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. Results: The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P < 0.001). Relief of subjective CSBM frequency, stool consistency and abdominal bloating were reported in 70%, 60%, and 47% of patients. After VSL#3 cessation, 44.4% of patients with symptom improvement experienced constipation recurrence mostly within one month. Conclusions: Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering Gut Flora to allevate constipation.

Moo In Park - One of the best experts on this subject based on the ideXlab platform.

  • change of fecal Flora and effectiveness of the short term vsl 3 probiotic treatment in patients with functional constipation
    Journal of Neurogastroenterology and Motility, 2015
    Co-Authors: Seong Eun Kim, Suck Chei Choi, Kyung Sik Park, Moo In Park, Jeong Eun Shin, Tae Hee Lee, Kee Wook Jung, Hoon Sup Koo, Seungjae Myung
    Abstract:

    Background/aims We investigated Gut Flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on Flora and symptom improvement. Methods Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and Flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. Results The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P Conclusions Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering Gut Flora to allevate constipation.

  • change of fecal Flora and effectiveness of the short term vsl 3 probiotic treatment in patients with functional constipation
    Journal of Neurogastroenterology and Motility, 2015
    Co-Authors: Suck Chei Choi, Kyung Sik Park, Moo In Park, Jeong Eun Shin, Kee Wook Jung, Seungjae Myung
    Abstract:

    Background/aims: We investigated Gut Flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on Flora and symptom improvement. Methods: Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and Flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. Results: The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P < 0.001). Relief of subjective CSBM frequency, stool consistency and abdominal bloating were reported in 70%, 60%, and 47% of patients. After VSL#3 cessation, 44.4% of patients with symptom improvement experienced constipation recurrence mostly within one month. Conclusions: Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering Gut Flora to allevate constipation.